Ah, the stock market. A bastion of rational thought, predictable trends, and calm, measured reactions. Or, at least, that’s what the textbooks tell us. In the era of Donald J. Trump, however, the market often resembles a particularly caffeinated squirrel navigating a minefield of Truth Social posts and impromptu policy pronouncements. Investors, it seems, have learned to strap in, brace for impact, and perhaps keep a bottle of antacids handy. The latest round of tariff threats, trade talks, and pharmaceutical deals has once again demonstrated that when Trump speaks, the market listens, sometimes with a shrug, sometimes with a gasp, and occasionally with a bewildered rally.
The Tariff Tango: A Two-Step of Volatility
Just when you thought trade wars were a relic of a bygone era (or at least last Tuesday), President Trump re-emerged with a fresh volley of tariff threats, proving that old habits die hard, especially when they involve import taxes. His latest target? The glamorous, globalized world of cinema. On September 29, via his preferred digital megaphone, Truth Social, Trump declared a whopping 100% tariff on all movies made outside the United States. The stated goal, naturally, was to rejuvenate the American film industry, which he claimed was being “stolen” by other countries.
The immediate market reaction was, as expected, a dramatic reel of red. Shares of streaming behemoth Netflix plunged 1.4% in premarket trading, while Warner Bros Discovery saw a 0.6% dip on September 29. Earlier iterations of this threat in May had sent Netflix down 3.3%, Walt Disney (-1.5%), and Warner Bros Discovery (-2.7%) spiraling, with the tech-heavy NASDAQ index losing 0.6%. The industry, naturally, was “flummoxed” by the logistics of such a tariff, given that modern filmmaking is a global ballet of production, financing, and post-production across multiple continents. An Irish film studio executive, perhaps with a flair for the dramatic, warned that the move would “put the coffin in the US film industry”. The irony, of course, is that Hollywood often chases international tax incentives, a practice Trump’s tariffs aim to reverse, potentially just driving up costs for everyone.
But the tariff dance wasn’t limited to Tinseltown. Trump also rolled out new tariffs on heavy trucks (a cool 25%), furniture, and lumber. This hit home-furnishing retailers hard, with Williams-Sonoma (WSM) dropping over 4% and RH (RH) falling more than 2% on September 30. On September 26, Wayfair (W) and Williams-Sonoma had already slid nearly 3%, and RH dropped 5%. Meanwhile, American truck manufacturer Paccar (PCAR) bucked the trend, jumping a respectable 6% on September 26, proving that one man’s tariff is another man’s profit.
Even sportswear giant Nike (NKE) found itself caught in the crossfire, warning investors of a projected $1.5 billion annual hit from tariffs, a 50% increase from its previous estimate. Despite this looming financial headwind, Nike shares surged 4.58% to $72.93 on October 1, defying a 31% net income decline, thanks to an earnings beat and optimism over wholesale growth and restructuring. It seems investors are willing to overlook a billion-dollar problem if the narrative is right, or perhaps they just really liked the new SKIMS collaboration.
Big Pharma’s Prescription for Panic (and Profit)
The pharmaceutical industry, perpetually under the microscope for drug pricing, received its own special attention from the Trump administration. The President had threatened a 100% tariff on branded pharmaceuticals starting October 1, unless companies committed to building manufacturing plants in the US or, more conveniently, agreed to slash prices. This was, as BMO Capital Markets analyst Evan Seigerman wryly observed, “more optics than bite,” a negotiating tactic designed to secure a “Trump ‘win'”.
And win he did, at least in the headlines. Pfizer (PFE), ever the pragmatist, swiftly secured a three-year reprieve from these tariffs by agreeing to cut US drug prices by up to 85% on some products, averaging 50% for its primary care treatments, and launching the “TrumpRx.gov” website for direct-to-consumer discounted sales. Wall Street, ever the optimist when uncertainty is removed, applauded. Pfizer shares, which had shed 10% earlier in 2025, surged 6.8% on September 30 and nearly 7% on October 1, hitting a 9-month high. The S&P 500 Pharmaceuticals Index also climbed 3.8%.
The “relief rally” wasn’t confined to American shores. European pharmaceutical giants like Roche (ROG) and Novartis (NOVN) saw their stocks rebound on the Zurich exchange, gaining 5.3% and 2.4% respectively, on the back of the Pfizer deal. Other major pharma players like Biogen (BIIB), Thermo Fisher Scientific (TMO), and Eli Lilly (LLY) also saw significant gains, rising between 8% and 10%. It seems that a good old-fashioned deal, even one born from a tariff threat, can bring a surprising amount of cheer to an industry accustomed to regulatory scrutiny.
Trade Deals and Soybean Swings: A Farmer’s Folly
The saga of US-China trade relations, particularly concerning soybeans, has been a recurring blockbuster in the Trump market drama. Farmers, often caught in the crossfire, have experienced whiplash-inducing market swings. Recently, President Trump took to Truth Social (again) to announce an upcoming meeting with Chinese President Xi Jinping in four weeks, with agriculture slated as a “major topic”. He also promised aid to farmers impacted by China’s reduced soybean purchases.
The market, ever responsive to even a hint of good news on the trade front, saw Chicago Board of Trade (CBOT) November soybeans rebound, rising 1.3% to $10.15 1/4 a bushel on October 1. On October 2, soybean contracts continued their upward trajectory, closing 10 to 12 cents higher, with the national average Cash Bean price up 10 cents at $9.35. This, of course, stands in stark contrast to earlier in September when soybean futures fell after a Trump-Xi phone call failed to yield concrete news on exports, sending November soybeans down 12 cents to $10.25-1/2 per bushel. The market’s memory, it seems, is as short as a news cycle, always ready to pivot on the latest presidential tweet, or rather, “Truth.”
Regulatory Rollercoaster: Capital Rules and Beyond
Beyond the headline-grabbing tariffs, the Trump administration has been quietly orchestrating a significant overhaul of U.S. capital rules, the most sweeping changes since the 2008 financial crisis. The goal? To cut “red tape” and, presumably, unleash the animal spirits of big banks. Senior industry executives are anticipating a “stunning victory,” expecting their capital requirements to fall. The proposed changes include narrowing the “Basel Endgame” capital hikes, reducing surcharges for global systemically important banks (GSIBs), and loosening key leverage constraints.
While banks like JPMorgan Chase (JPM) and Bank of America (BAC) might face headwinds from compressed net interest margins in a lower-rate environment, the overall sentiment among large lenders is optimistic. However, not everyone is cheering. Critics warn that these rollbacks could leave the financial system vulnerable, with some estimating a potential $200 billion reduction in banking system capital. It’s a classic Trumpian move: deregulate, stimulate, and let the market sort out the “unintended consequences” later.
The Grand Finale (for now)
In the whirlwind world of Trump’s market impact, contradictions are the only constant. Tariffs are announced to protect industries, yet they often lead to increased costs and warnings from companies like Nike. Threats of punitive measures against pharmaceutical companies magically transform into “deals” that send their stock prices soaring. And a single post on Truth Social can send soybean futures bouncing like a super ball.
Major indices have, for the most part, continued their upward march, albeit with occasional jitters. On September 26, the Dow Jones Industrial Average (DIA) soared 0.8% to 46,316, the NASDAQ Composite (IXIC) jumped 0.32% to 22,455, and the S&P 500 (SPY) gained 0.56% to 6,641. Even on September 30, the S&P 500, Dow Jones, and Nasdaq 100 all closed higher. Yet, beneath the surface, economists at UCLA Anderson Forecast are predicting a “stagflation-lite” scenario, with higher inflation and unemployment, partly due to these very tariffs. And the specter of a government shutdown, which Trump has threatened to leverage for cutting “Democrat agendas,” still looms, with Moody’s Analytics warning it could “wreak havoc on the financial markets”.
So, as the market continues its unpredictable dance to the tune of presidential pronouncements, investors are left to ponder: is this chaos a feature or a bug? And more importantly, how many more “deals” and “wins” can one market endure before it simply throws its hands up in exasperation?
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.